Longeveron (LGVN) Reports FY24 Results, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as Iran tensions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
February 28, 2025 4:04 PM ESTPivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-BÂ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-BÂ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-BÂ in mild Alzheimers diseaseWHO International Nonproprietary Names (INN) Expert Committee approved laromestrocel for the non-proprietary name of... More
